Joanne Donovan, MD, PhD
Adjunct Clinical Associate Professor
Boston University School of Medicine
Dept of Medicine
Gastroenterology

MD, Harvard Medical School
PhD, Massachusetts Institute of Technology
MS, Massachusetts Institute of Technology




VA Boston Healthcare System


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Cowen L, Mancini M, Martin A, Lucas A, Donovan JM. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry. BMC Neurol. 2019 May 02; 19(1):84. PMID: 31046703
     
  2. Finanger E, Vandenborne K, Finkel RS, Lee Sweeney H, Tennekoon G, Yum S, Mancini M, Bista P, Nichols A, Liu H, Fretzen A, Donovan JM. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-?B Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2019; 6(1):43-54. PMID: 30452422
     
  3. Donovan JM, Zimmer M, Offman E, Grant T, Jirousek M. A Novel NF-?B Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 05; 57(5):627-639. PMID: 28074489
     
  4. Santos RD, Raal FJ, Donovan JM, Cromwell WC. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9. PMID: 25911076
     
  5. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012 Nov 06; 126(19):2283-92. PMID: 23060426
     
  6. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012 May; 33(9):1142-9. PMID: 22507979; PMCID: PMC3751967
     
  7. Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010; 10(5):305-14. PMID: 20860413
     
  8. Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9. PMID: 19940418
     
  9. Donovan JM, Plone M, Dagher R, Bree M, Marquis J. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005; 1054:492-4. PMID: 16339704
     
  10. Eckhardt ER, Wang DQ, Donovan JM, Carey MC. Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers. Gastroenterology. 2002 Apr; 122(4):948-56. PMID: 11910347
     
Showing 10 of 12 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 12 publications over 8 distinct years, with a maximum of 3 publications in 2002

YearPublications
20023
20051
20091
20101
20122
20141
20171
20192

Contact for Mentoring:

72 E. Concord Street
Boston MA 02118
Google Map


Donovan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Similar People
_
Same Department